Medical Cannabis in Parkinson Disease: Real-Life Patients' Experience

Clinical Neuropharmacology

Volumn 40, Issue 6, 2017, Pages 268-272

  Balash, Yacov ^a,b   Bar Lev Schleider, Lihi ^c   Korczyn, Amos D ^b   Shabtai, Herzel ^a   Knaani, Judith ^a   Rosenberg, Alina ^b   Baruch, Yehuda ^d   Djaldetti, Ruth ^b,e   Giladi, Nir ^a,b   Gurevich, Tanya ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Tikun Olam Ltd   (Israel)

^d One World Cannabis Ltd   (Israel)

^e RABIN MEDICAL CENTER   (Israel)

Author keywords

adverse effects; medical cannabis; motor symptoms; nonmotor symptoms; Parkinson disease; therapeutics

Indexed keywords

MEDICAL CANNABIS;

ADULT; AGED; AMNESIA; ANALGESIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONFUSION; COUGHING; DEPRESSION; DISEASE DURATION; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG WITHDRAWAL; DYSPNEA; EFFECT SIZE; FATIGUE; FEMALE; HALLUCINATION; HOEHN AND YAHR SCALE; HUMAN; MALE; MIDDLE AGED; MUSCLE RIGIDITY; OBSERVATIONAL STUDY; PARKINSON DISEASE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SLEEP; SMOKING; TELEPHONE INTERVIEW; TREATMENT DURATION; TREATMENT INTERRUPTION; TREMOR; UNCONSCIOUSNESS; UNSTEADINESS; VERY ELDERLY; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; MULTICENTER STUDY; PATIENT SATISFACTION; PILOT STUDY; PSYCHOLOGY; QUESTIONNAIRE;

AGED; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; MALE; MEDICAL MARIJUANA; MIDDLE AGED; PARKINSON DISEASE; PATIENT SATISFACTION; PILOT PROJECTS; RETROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES;

EID: 85035313562     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000246     Document Type: Article

References (23)

1. Lotan I, Treves TA, Roditi Y, et al. Cannabis (medicalmarijuana) treatment for motor and non-motor symptoms of Parkinson disease: An open-label observational study. Clin Neuropharmacol 2014;37:41-44.
2. Frankel JP, Hughes A, Lees AJ, et al. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990;53:436.
3. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004;63: 1245-1250.
4. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-48.
5. Venderová K, Ruzicka E, Vorísek V, et al. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord 2004;19:1102-1106.
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976.
7. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Science; 2002.
8. Morris SB. Estimating effect sizes from pretest-posttest-control group designs. Organizational Research Methods 2008;11:364-386.
9. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
10. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327-360.
11. Pearce DD, Mitsouras K, Irizarry KJ. Discriminating the effects of Cannabis sativa and Cannabis indica: Aweb survey of medical cannabis users. J Altern Complement Med 2014;20:787-791.
12. Gage SH, Munafò MR, MacLeod J, et al. Cannabis and psychosis. Lancet Psychiatry 2015;2:380.
13. Bloomfield MA, Morgan CJ, Kapur S, et al. The link between dopamine function and apathy in cannabis users:An [18F]-DOPAPETimaging study. Psychopharmacology (Berl) 2014;231:2251-2259.
14. Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl JMed 2014;370:2219-2227.
15. Davis JP, Smith DC, Morphew JW, et al. Cannabis withdrawal, posttreatment abstinence, and days to first cannabis use among emerging adults in substance use treatment: A prospective study. J Drug Issues 2016; 46:64-83.
16. McRae-Clark AL, Baker NL, Gray KM, et al. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend 2015;156:29-37.
17. Burgdorf JR, Kilmer B, Pacula RL. Heterogeneity in the composition of marijuana seized in California. Drug Alcohol Depend 2011;117:59-61.
18. Giuffrida A, McMahon LR. In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat 2010;91: 90-103.
19. Sanudo-Pena MC, Tsou KJ, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999;65:703-713.
20. Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000;14: 1432-1438.
21. Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002;109: 451-460.
22. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612-1623.
23. Naftali T. Medical cannabis. Harefuah 2016;155:79-82.